BioCentury
ARTICLE | Clinical News

ABBV-8E12: Ph II started

February 1, 2017 10:14 PM UTC

AbbVie began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate IV ABBV-8E12 in about 180 patients. AbbVie has exclusive, worldwide rights to develop and commercialize the product fro...